FrancophonIA/ELRC3.0 huggingface dataset:
English: Both active substances in Combivir, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs).
Maltese: Iż-żewġ sustanzi attivi f'Combivir, il-lamivudina u z-zidovudina, huma inibituri nukleosidiċi tattranskrittażi inversa (nucleoside reverse transcriptase inhibitors) (NRTIs).
English: This is a summary of the European Public Assessment Report (EPAR) for Combivir.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Combivir.
English: The European Commission granted a marketing authorisation valid throughout the EU for Combivir on 18 March 1998.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal għal Combivir fit-18 ta' Marzu 1998.
English: Combivir lamivudine / zidovudine
Maltese: Sommarju tal-EPAR għall-pubbliku lamivudina/zidovudina
English: Why is Combivir approved?
Maltese: Għaliex ġie approvat Combivir?
English: Combivir was absorbed in the same way as the separate tablets.
Maltese: Combivir ġie assorbit bl-istess mod bħall-pilloli separati.
English: Combivir, an antiviral medicine, is used in combination with at least one other antiviral medicine to treat patients infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Combivir, mediċina antivirali, jintuża flimkien ma' mill-inqas mediċina antivirali oħra biex jikkura pazjenti infettati bil-virus tal-immunodefiċjenza umana (HIV), il-virus li jikkawża s-sindromu millimmonudefiċjenza akkwżita (AIDS).
English: Combivir contains two active substances, lamivudine and zidovudine.
Maltese: Combivir fih żewġ sustanzi attivi, il-lamivudina u z-zidovudina.
English: The two groups also had similar rises in CD4 cell counts.
Maltese: Iż-żewġ gruppi kellhom ukoll żidiet simili fl-għadd taċ-ċelloli CD4.
English: The company also compared Combivir to separate tablets of lamivudine and zidovudine in 75 patients aged over 12 years who had not taken treatment for HIV infection before.
Maltese: Il-kumpanija qabblet ukoll Combivir ma' pilloli separati tal-lamivudina u z-zidovudina f'75 pazjent ta' aktar minn 12-il sena li ma kinux ħadu kura għall-infezzjoni tal-HIV qabel.
English: What are the risks associated with Combivir?
Maltese: X'inhuma r-riskji assoċjati ma' Combivir?
English: Children weighing less than 14 kg will need to use separate oral solutions containing lamivudine and zidovudine.
Maltese: Tfal li jiżnu inqas minn 14-il kg jeħtieġ li jużaw taħlitiet orali separati li fihom illamivudina u z-zidovudina.
English: How is Combivir used?
Maltese: Kif jaħdem Combivir?
English: In children (below 12 years of age) weighing between 14 and 30 kg, the dose depends on their weight.
Maltese: Fit-tfal (taħt it-12-il sena) li jiżnu bejn 14 u 30 kg, id-doża tiddependi mill-piż tagħhom.
English: Combivir, taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level.
Maltese: Combivir, meħud flimkien ma' mill-inqas mediċina waħda antivirali oħra, inaqqas l-ammont ta' HIV fiddemm u jżommu f'livell baxx.
English: They work in similar ways by blocking the activity of reverse transcriptase, an enzyme made by the HIV virus that allows it to reproduce itself in the cells it has infected.
Maltese: Huma jaħdmu b'mod simili billi jimblokkaw l-attività tat-traskrittażi inversa, enzima prodotta mill-virus tal-HIV li jħalliha tirripproduċi ruħha fiċ-ċelloli li tkun infettat.
English: For the full list of all the side effects of Combivir and restrictions on its use, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u tar-restrizzjonijiet irrappurtati b'Combivir, ara l-fuljett ta' tagħrif.
English: The studies showed that the active substances taken together could reduce viral loads (the level of HIV in the blood) and allow CD4 cell counts to rise after up to one year of treatment.
Maltese: L-istudji wrew li s-sustanzi attivi meħudin flimkien setgħu jnaqqsu t-tagħbijiet virali (il-livell tal-HIV fid-demm) u jippermettu l-għadd ta' ċelloli CD4 biex jogħla wara mhux aktar minn sena ta' kura.
English: Combivir does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS.
Maltese: Combivir ma jfejjaqx l-infezzjoni tal-HIV jew l-AIDS, iżda jista' jittardja lħsara prodotta lis-sistema immunitarja u l-iżvilupp ta' infezzjonijiet u mard assoċjat mal-AIDS.
English: The recommended dose of Combivir for patients over 12 years of age who weigh at least 30 kg is one tablet taken twice a day.
Maltese: Id-doża rakkomandata ta' Combivir għal pazjenti ta' aktar minn 12-il sena li jiżnu mill-inqas 30 kg hija pillola waħda darbtejn kuljum.
English: The company also compared how the body absorbed the Combivir combination tablet and the separate tablets.
Maltese: Il-kumpanija qabblet ukoll kif il-ġisem assorba l-pillola ta' kombinazzjoni ma' Combivir u l-pilloli separati.
English: CD4 cells (also called CD4 T cells) are white blood cells that are important for fighting infections, but they are killed by HIV.
Maltese: Iċ-ċelloli CD4 (li jissejħu wkoll ċelloli CD4 T) huma ċelloli tad-demm bojod li huma importanti biex jiġġieldu linfezzjonijiet, iżda dawn jinqatlu mill-HIV.
English: The recommended doses of Combivir in children produced similar levels of the two active substances as in older patients.
Maltese: Id-dożi rakkomandati ta' Combivir fit-tfal ipproduċew livelli simili taż-żewġ sustanzi attivi bħal f'pazjenti ikbar fl-età.
English: If patients need to stop taking lamivudine or zidovudine, or need to take different doses because of problems with their kidneys, liver or blood, they will need to take medicines containing lamivudine or zidovudine separately.
Maltese: Jekk il-pazjenti jeħtieġ li jwaqqfu l-lamivudina jew iz-zidovudina, jew jeħtieġ li jieħdu dożi differenti minħabba problemi fil-kliewi, fil-fwied jew fid-demm, jeħtieġ li jieħdu mediċini li fihom il-lamivudina jew iz-zidovudina separati.
English: The most common side effects with Combivir (which may affect more than 1 patient in 10) are diarrhoea and nausea (feeling sick).
Maltese: L-effetti sekondarji l-aktar komuni b'Combivir (li jistgħu jaffettwaw aktar minn pazjent 1 minn kull 10) huma dijarrea u dardir (tħossok ma tiflaħx).
English: Patients taking Combivir and those taking the two active substances separately had similar falls in viral load.
Maltese: Il-pazjenti li jieħdu Combivir u dawk li jieħdu ż-żewġ sustanzi attivi separatament kellhom tnaqqis simili fit-tagħbija virali.
English: CHMP considered that combining the active ingredients in a single tablet may be of advantage because it can improve how well patients stick to the prescribed treatment and this can help to prevent HIV becoming resistant to treatment.
Maltese: Il-pazjenti li ma jistgħux jibilgħu pilloli jistgħu jfarrku l-pilloli, iżiduhom ma' ammont żgħir ta' ikel jew xorb u jibilgħuha immedjatament.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Combivir's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) tal-Aġenzija ddeċieda li l-benefiċċji ta' Combivir huma akbar mir-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fissuq.
English: Eucalyptus leaf EMA/HMPC/300235/2013
Maltese: Weraq tal-Ewkaliptus EMA/HMPC/300235/2013
English: EMA/HMPC/300235/2013
Maltese: EMA/HMPC/300235/2013 Il-Kumitat għall-Prodotti Mediċinali Erbali (HMPC)
English: Eucalyptus leaf is the common name for the whole or cut leaf of the tree Eucalyptus globulus Labill.
Maltese: Il-weraq tal-Ewkaliptus huwa l-isem komuni għall-werqa sħiħa jew maqtugħa tas-siġra Eucalyptus globulus Labill.
English: In its assessment, the HMPC considered the results of laboratory tests as well as studies in patients looking in particular at the effects of a component of eucalyptus leaf, called 1,8 cineole (also known as eucalyptol).
Maltese: Fil-valutazzjoni tiegħu, l-HMPC ikkunsidra r-riżultati ta' testijiet fil-laboratorju kif ukoll studji fuq pazjenti u b'mod partikolari ħares lejn l-effetti ta' komponent ta' weraq tal-Ewkaliptus, magħruf bħala 1,8 cineole (magħruf ukoll bħala eucalyptol).
English: Eucalyptus leaf
Maltese: Weraq tal-Ewkaliptus
English: How are eucalyptus leaf medicines approved in the EU?
Maltese: Kif jiġu approvati fl-UE l-mediċini tal-weraq tal-Ewkaliptus ?
English: Other information about eucalyptus leaf medicines
Maltese: Aktar informazzjoni dwar il-mediċini Weraq tal-Ewkaliptus
English: Further information on the HMPC assessment of eucalyptus leaf medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Maltese: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: The HMPC recommended that eucalyptus leaf medicines should not be used in children under 30 months of age because of the risk of laryngospasm (contraction of the vocal cords).
Maltese: L-HMPC irrakkomanda li mediċini li fihom weraq tal-Ewkaliptus ma għandhomx jintużaw fit-tfal taħt it30 xahar minħabba r-riskju ta' larinġospażmu (kontrazzjoni tal-kordi vokali).
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Maltese: Dan ifisser li, għalkemm m'hemmx biżżejjed evidenza minn provi kliniċi, l-effikaċja ta' dawn il-mediċini erbali hija plawsibbli u hemm evidenza li ilhom jintużaw b'dan il-mod b'mod sigur għal mill-inqas 30 sena (inkluż mill-inqas 15-il sena fl-UE).
English: The studies indicated that 1,8 cineole might have an effect in diseases of the airways.
Maltese: L-istudji indikaw li 1,8 cineole jista' jkollu effett f'mard tal-passaġġi tal-arja.
English: If symptoms persist for longer than a week, a doctor should be consulted.
Maltese: Jekk is-sintomi jippersistu għal aktar minn ġimgħa, għandu jiġi kkonsultat tabib.
English: Comminuted preparations of eucalyptus leaf should only be used in adults and children over the age of 12 years, while tincture preparations should only be used in adults due to high content of ethanol (pure alcohol).
Maltese: Preparazzjonijiet imfarrka ta' weraq tal-Ewkaliptus għandhom jintużaw biss fl-adulti u fit-tfal ta' aktar minn 12-il sena, filwaqt li preparazzjonijiet tintura għandhom jintużaw fl-adulti minħabba l-kontenut
English: Further information on the risks associated with eucalyptus leaf medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Maltese: Aktar informazzjoni dwar ir-riskji assoċjati mal-mediċini li fihom il-weraq tal-Ewkaliptus, inkluż ilprekawzjonijiet xierqa għall-użu sigur tagħhom, tinsab fil-monografu taħt it-tab ‘Id-dokumenti kollha' fis-sit elettroniku tal-Aġenzija:
English: What are the risks associated with eucalyptus leaf medicines?
Maltese: X'inhuma r-riskji assoċjati mal-mediċini tal-weraq tal-Ewkaliptus ?
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of eucalyptus leaf.
Maltese: Dan id-dokument huwa sommarju tal-konklużjonijiet xjentifiċi li wasal għalihom il-Kumitat għallProdotti Mediċinali Erbali (HMPC) dwar l-użu mediċinali ta' weraq tal-Ewkaliptus.
English: Herbal medicines containing eucalyptus leaf are usually available as comminuted herbal material for the preparation of a herbal tea to be drunk, an infusion to be inhaled or a liquid to be taken by mouth.
Maltese: Mediċini erbali li fihom il-weraq tal-Ewkaliptus huma ġeneralment disponibbli bħala materjal erbali mfarrak għall-preparazzjoni ta' tè erbali għax-xorb, infużjoni biex tittieħed man-nifs jew likwidu biex jittieħed mill-ħalq.
English: What is eucalyptus leaf?
Maltese: X'inhu l-weraq tal-Ewkaliptus ?
English: Eucalyptus leaf can also be found in combination with other herbal substances in some herbal medicines.
Maltese: Il-weraq tal-Ewkaliptus jista' jinstab f'kombinazzjoni ma' sustanzi erbali oħra f'xi mediċini erbali.
English: Preparations from dried eucalyptus leaf are obtained by comminuting (reducing into tiny pieces) the dried leaves of older branches of the tree, or by using them to produce a tincture (an alcoholic extract of the plant material).
Maltese: Preparazzjonijiet minn weraq tal-Ewkaliptus imnixxef jinkisbu billi l-weraq imnixxfin tal-eqdem friegħi tas-siġra jiġu mfarrka (mnaqqsa f'biċċiet żgħar), jew billi jintużaw biex jipproduċu tintura (estratt alkoħoliku tal-materjal tal-pjanta).
English: What evidence supports the use of eucalyptus leaf medicines?
Maltese: X'evidenza tappoġġa l-użu tal-mediċini tal-weraq tal-Ewkaliptus ?
English: 210 ml
Maltese: Flixkun (HDPE) 210 ml
English: Package size mg/ml
Maltese: Mnejn jingħata Il-pakkett
English: 1 bottle + 1 measuring spoon
Maltese: 1 flixkun+ mgħarfa għall-qies
English: Oral solution
Maltese: Użu orali
English: Packaging
Maltese: (konċentrazzjoni)
English: Singapore 637026
Maltese: Singapor 637026
English: Ltd. 1 Tuas View Drive
Maltese: 1 Tuas View Drive
English: Both -2.5
Maltese: It-tnejn -2.5
English: No data are available.
Maltese: M'hemm lebda dejta disponibbli.
English: Percentage [%]
Maltese: Perċentwal [%]
English: Both <0.001a,d
Maltese: 001a,d
English: Biotransformation / Elimination
Maltese: Bijotrasformazzjoni / Eliminazzjoni
English: Placebo (n = 281)
Maltese: Plaċebo (n = 281)
English: 1 pre-filled pen Component of a multipack.
Maltese: Komponent ta' pakkett multiplu.
English: Step 3: Inject
Maltese: Pass 3: Injetta
English: Sodium hydroxide (for pH adjustment) Glacial acetic acid
Maltese: Sodium hydroxide (għall-aġġustament tal-pH) Glacial acetic acid
English: Do not place your finger on the plunger while inserting the needle.
Maltese: Meta tkun lest, neħħi subgħajk, u aqla' bil-mod is-siringa mill-ġilda tiegħek u mbagħad itlaq il-ġilda maqrusa.
English: Placebo (n = 316)
Maltese: Plaċebo (n = 316)
English: Hypersensitivity reactions including rash, swelling/oedema and urticaria
Maltese: Reazzjonijiet ta' sensittività eċċessiva inklużi raxx, nefħa/edima u urtikarja
English: Common a
Maltese: Komuni a
English: click
Maltese: klikk
English: No interaction with oral contraceptives (ethinyl estradiol/norgestimate) or sumatriptan was observed in studies with healthy volunteers.
Maltese: Ma dehritx interazzjoni ma' kontraċettivi orali (ethinyl estradiol/norgestimat) jew sumatriptan fi studji fost voluntiera f'saħħithom.
English: CI = confidence interval; MMD = monthly migraine days; HIT-6 = Headache Impact Test; MIDAS = Migraine Disability Assessment a
Maltese: MMD = jiem b'emigranja fix-xahar; HIT6 = Test tal-Impatt tal-Uġigħ ta' Ras; MIDAS = Valutazzjoni tad-Diżabilità minħabba l-Emigranja a
English: Most of these side effects are mild to moderate.
Maltese: Ħafna mill-effetti sekondarji huma minn ħfief sa moderati.
English: For the full list of excipients, see section 6.1.
Maltese: Għal-lista sħiħa tal-eċċipjenti, ara sezzjoni 6.1.
English: Both <0.001a
Maltese: 001a
English: Also contains: sucrose, polysorbate 80, sodium hydroxide, glacial acetic acid, water for injections.
Maltese: Fih ukoll: sucrose, polysorbate 80, sodium hydroxide, glacial acetic acid, ilma għall-injezzjonijiet.
English: Erenumab is a fully human IgG2 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Maltese: IgG2 kompletament uman prodott permezz ta' teknoloġija tadDNA rikombinanti f'ċelloli tal-ovarji tal-ħamster Ċiniż (Chinese hamster ovary - CHO).
English: 955 patients were randomised in a 1:1:1 ratio to receive 140 mg (n = 319) or 70 mg (n = 317) erenumab or placebo (n = 319).
Maltese: 955 pazjent kienu randomizzati fi proporzjon ta' 1:1:1 biex jingħataw 140 mg (n = 319) jew 70 mg (n = 317) erenumab jew plaċebo (n = 319).
English: In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Maltese: (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000); rari ħafna (<1/10,000).
English: A total of 294 patients (92%) for 140 mg, 287 (91%) patients for 70 mg and 284 patients (89%) in the placebo arm completed the double-blind phase.
Maltese: Total ta' 294 pazjent (92%) għal 140 mg, 287 pazjent (91%) għal 70 mg u 284 pazjent (89%) fil-fergħa ta' plaċebo lestew il-fażi double-blind.
English: A total of over 2,500 patients (more than 2,600 patient years) have been treated with Aimovig in registration studies.
Maltese: Total ta' aktar minn 2,500 pazjent (aktar minn 2,600 sena ta' pazjent) kienu ttrattati b'Aimovig waqt studji ta' reġistrazzjoni.
English: Treatment difference (95% CI)
Maltese: Differenza fil-kura (95% CI)
English: - The other ingredients are sucrose, polysorbate 80, sodium hydroxide, glacial acetic acid, water for injections.
Maltese: - Is-sustanzi mhux attivi l-oħra huma sucrose, polysorbate 80, sodium hydroxide, glacial acetic acid, ilma għall-injezzjonijiet.
English: What Aimovig contains - The active substance is erenumab.
Maltese: X'fih Aimovig - Is-sustanza attiva hi erenumab.
English: MIDAS total Mean changec (95% CI)
Maltese: Total MIDAS Bidla fil-medjac (95% CI)
English: Episodic migraine
Maltese: Emigranja episodika
English: The injection must be administered within 5 minutes.
Maltese: L-injezzjoni għandha tingħata fi żmien 5 minuti.
English: New syringe(s)
Maltese: Spezzjona s-siringa(i).
English: Following a single 140 mg intravenous dose, the mean (SD) volume of distribution during the terminal phase (Vz) was estimated to be 3.86 (0.77) l.
Maltese: Wara doża waħda ta' 140 mg ġol-vina, il-volum medju (SD) ta' distribuzzjoni matul il-fażi terminali (Vz) kien stmat għal 3.86 (0.77) l.
English: Elderly patients (>65 years), patients with opioid overuse in study in chronic migraine, patients with medication overuse in study in episodic migraine, and also patients with pre-existing myocardial infarction, stroke, transient ischaemic attacks, unstable angina, coronary artery bypass surgery or other re-vascularisation procedures within 12 months prior to screening were excluded.
Maltese: Kienu esklużi l-pazjenti anzjani (>65 sena), pazjenti b'użu eċċessiv ta' opjode, u anki pazjenti b'infart mijokardjali eżistenti minn qabel, puplesija, attakki iskemiċi temporanji, anġina instabbli, kirurġija tal-bypass tal-arterja koronarja jew proċeduri oħrajn ta' rivaskularizzazzjoni fi żmien 12-il xahar qabel l-iskrinjar.
English: Injection site reactions b
Maltese: mhux applikabbli b
English: Patients had a median age of 43 years, 83% were female and 94% were white.
Maltese: Il-pazjenti kellhom età medjana ta' 43 sena, 83% kienu nisa u 94% kienu bojod.
English: At Week 52, the proportion of subjects who achieved a ≥50% reduction in MMD from baseline was 61.0% in the 70 mg ATP and 64.9% in the 140 mg ATP group.
Maltese: Fit-52 Ġimgħa, il-proporzjon ta' suġġetti li kisbu tnaqqis fl-MMD ta' ≥50% millinja bażi kien ta' 61.0% waqt l-ATP u ta' 64.9% fil-grupp mogħti 140 mg waqt l-ATP.
English: Patients with renal impairment Patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) have not been studied.
Maltese: Pazjenti b'indeboliment tal-kliewi Il-pazjenti b'indeboliment tal-kliewi sever (eGFR <30 ml/min/1.73 m2) ma ġewx studjati.
English: Pharmacotherapeutic group: Analgetics, antimigraine preparations, ATC code: N02CX07
Maltese: Analġetiċi, tħejjijiet għal kontra l-emigranja, Kodiċi ATC:
English: Illustration of the Aimovig 140 mg pen (with dark blue body, grey start button, orange cap and yellow safety guard)
Maltese: Illustrazzjoni tal-pinna Aimovig 140 mg (b'qafas blu skur, bil-buttuna tal-bidu l-griża, bl-għatu l-oranġjo u bil-protezzjoni tas-sigurtà s-safra)
English: Note: The prescribed dose of Aimovig is either 70 mg or 140 mg.
Maltese: Nota: Id-doża ordnata ta' Aimovig hija ta' 70 mg jew ta' 140 mg.
English: For exploratory endpoints, no p-value is presented.
Maltese: Għal endpoints esploratorji, ma ġie ppreżentat l-ebda valur p.
English: 667 patients were randomised in a 3:2:2 ratio to receive placebo (n = 286) or 70 mg (n = 191) or 140 mg (n = 190) erenumab, stratified by the presence of acute medication overuse (present in 41% of overall patients).
Maltese: 667 pazjent kienu randomizzati fi proporzjon ta' 3:2:2 biex jirċievu plaċebo (n = 286) jew 70 mg (n = 191) jew 140 mg (n = 190) erenumab, stratifikati skont il-preżenza ta' użu eċċessiv ta' mediċini akuti (preżenti f'41% tal-popolazzjoni globali tal-pazjenti).
English: ≥50% MMD responders Percentage [%]
Maltese: ≥50% pazjenti MMD li rrispondew għall-kurac Perċentwal [%]
English: Aimovig 140 mg injection erenumab
Maltese: Aimovig 140 mg injezzjoni erenumab
English: Patient-reported outcome measures HIT-6
Maltese: Għal HIT-6:
English: Multipack containing 3 (3x 1) pre-filled pens
Maltese: Pakkett multiplu li fih 3 (3x1) pinen mimlija għal-lest
English: Patients had a median age of 42 years, 85% were female and 89% were white.
Maltese: Il-pazjenti kellhom età medjana ta' 42 sena, 85% kienu nisa u 89% kienu bojod.
English: CGRP is a neuropeptide that modulates nociceptive signalling and a vasodilator that has been associated with migraine pathophysiology.
Maltese: CGRP huwa neuropeptide li jimmodula s-sinjalazzjoni noċiċettiva u vażodilatur li ġie assoċjat ma' patofiżjoloġija tal-emigranja.
English: Aimovig works by blocking the activity of the CGRP molecule, which has been linked to migraine (CGRP stands for calcitonin gene-related peptide).
Maltese: Aimovig jaħdem billi jimblokka l-attività tal-molekula CGRP, li kienet marbuta mal-emigranja (CGRP tfisser peptide relatat mal-ġene tal-calcitonin).
English: Patients were re-randomised in the active treatment phase (ATP) to 70 mg or 140 mg erenumab.
Maltese: Il-pazjenti reġgħu kienu randomizzati waqt il-fażi ta' trattament attiv (ATP) għal 70 mg jew 140 mg erenumab.
English: Aimovig (erenumab) was evaluated for prophylaxis of episodic migraine in a randomised, multicentre, 24-week, placebo-controlled, double-blind study in patients suffering from migraine with or without aura (4-14 migraine days per month).
Maltese: Aimovig (erenumab) kien evalwat għall-profilassi ta' emigranja episodika fi studju randomizzat, multiċentriku, ta' 24 ġimgħa, ikkontrollat bi plaċebo, double-blind f'pazjenti li jbatu minn emigranja b'awra jew mingħajrha (4-14-il jum b'emigranja fix-xahar).
English: The mutagenic potential of erenumab has not been evaluated; however, monoclonal antibodies are not expected to alter DNA or chromosomes.
Maltese: Il-potenzjal mutaġeniku ta' erenumab ma ġiex evalwat; madankollu, l-antikorpi monoklonali mhumiex mistennija li jbiddlu d-DNA jew il-kromożomi.
English: Multipack: 3 (3 packs of 1) pre-filled pens
Maltese: Soluzzjoni għall-injezzjoni Pakkett multiplu: 3 (3 pakketti ta' 1) pinen mimlija għal-lest
English: Common: may affect up to 1 in 10 people - allergic reactions such as rash, swelling or hives - constipation - itching - muscle spasms - injection site reactions, such as pain, redness and swelling where the injection is given.
Maltese: Komuni: jistgħu jaffettwaw sa 1 minn kull 10 persuni - reazzjonijiet allerġiċi bħal raxx, nefħa jew ħorriqija - stitikezza - ħakk - spażmi fil-muskoli - reazzjonijiet fis-sit tal-injezzjoni, bħal uġigħ, ħmura u nefħa fejn tingħata l-injezzjoni.
English: ≥75% MMD
Maltese: ≥75% pazjenti MMD li rrispondew għall-kura
English: Aimovig 70 mg injection erenumab
Maltese: Aimovig 70 mg injezzjoni erenumab
English: Illustration of the Aimovig 70 mg pen (with light blue body, purple start button, white cap and green safety guard)
Maltese: Illustrazzjoni tal-pinna Aimovig 70 mg (b'qafas blu ċar, bil-buttuna tal-bidu l-vjola, bl-għatu l-abjad u bil-protezzjoni tas-sigurtà l-ħadra)